Enzastaurin's Effect on Tumors Resistant to Anti-EGFR Drugs
Author Information
Author(s): Gelardi T, Caputo R, Damiano V, Daniele G, Pepe S, Ciardiello F, Lahn M, Bianco R, Tortora G
Primary Institution: Università di Napoli Federico II
Hypothesis
Can enzastaurin inhibit the growth of tumors that are resistant to anti-EGFR drugs?
Conclusion
Enzastaurin effectively inhibits tumor growth and overcomes resistance to gefitinib in both sensitive and resistant cancer cells.
Supporting Evidence
- Enzastaurin showed marked inhibitory activity against both sensitive and gefitinib-resistant cancer cells.
- The combination of enzastaurin and gefitinib resulted in a significant increase in median survival in treated mice.
- Enzastaurin inhibited the expression of proteins associated with EGFR drug resistance.
Takeaway
Enzastaurin is a medicine that helps fight cancer by stopping tumors from growing, even when they don't respond to other treatments.
Methodology
The study evaluated enzastaurin's effects on various human cancer cell lines and in nude mice, measuring tumor growth and protein expression.
Limitations
The study primarily focused on specific cancer cell lines and may not generalize to all tumor types.
Participant Demographics
The study involved human cancer cell lines and nude mice, with no specific demographic data provided.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website